Feasibility & Characterization of Project: EVO Monitor Cognitive Measurements
Status: | Not yet recruiting |
---|---|
Conditions: | Healthy Studies |
Therapuetic Areas: | Other |
Healthy: | No |
Age Range: | 40 - 55 |
Updated: | 6/8/2016 |
Start Date: | June 2016 |
End Date: | September 2016 |
Contact: | Ted Riley |
Email: | triley@promedica-intl.com |
Phone: | 714-460-7363 |
A Study to Assess the Feasibility of and to Characterize Project: EVO Monitor Cognitive Function Measurements When Played Daily, Weekly, or Multiple Times Per Day in Adults 40-55 Years Old
This is an open-label study in adults to assess at-home Project: EVO Monitor measurements
over repeat play cycles. The study has three arms:playing multiple times per day, once
daily, and once weekly for 4 to 8 weeks.
over repeat play cycles. The study has three arms:playing multiple times per day, once
daily, and once weekly for 4 to 8 weeks.
This is an open-label study in adults ages 40 to 55 to assess Project: EVO Monitor
measurements over repeat play cycles. The study has three arms: adults playing multiple
times per day, adults playing once daily, and adults playing once weekly. The investigators
plan to evaluate 76 participants (N = 30 in the daily and weekly arms, and N=16 in the
multiple times per day arm) in two sites over a 4 to 8 week study period. The study period
includes 2 in-clinic sessions and scheduled, at-home game play of the short (less than 7
minutes) Project: EVO Monitor.
measurements over repeat play cycles. The study has three arms: adults playing multiple
times per day, adults playing once daily, and adults playing once weekly. The investigators
plan to evaluate 76 participants (N = 30 in the daily and weekly arms, and N=16 in the
multiple times per day arm) in two sites over a 4 to 8 week study period. The study period
includes 2 in-clinic sessions and scheduled, at-home game play of the short (less than 7
minutes) Project: EVO Monitor.
Inclusion Criteria:
- Age: 40-55 at the time of informed consent
- Ability to follow written and verbal instructions (English).
- Male and Female (Gender-matched).
- Ability to comply with all the testing and requirements.
Exclusion Criteria:
- Current, controlled (requiring a restricted medication) or uncontrolled,
self-reported psychiatric diagnosis with significant symptoms such as post-traumatic
stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe
obsessive compulsive disorder, severe depressive or severe anxiety disorder, conduct
disorder, attention deficit disorder, autism spectrum disorder, or other symptomatic
manifestations that in the opinion of the Investigator that may confound study
data/assessments.
- Current self-reported community diagnosis of cognitive ailments such as dementia,
Alzheimer's disease, stroke, traumatic brain injury, or other diseases that in the
opinion of the Investigator that may confound study data/assessments.
- Current diagnosis of severe learning disorder, dyslexia, or dyscalculia.
- Current subjective complaints of inattention or memory loss.
- Current use of psychotropic medication, prescription or otherwise.
- Currently undergoing psychotherapy, behavioral therapy, or occupational therapy.
- Motor condition that prevents game playing, as observed by investigator.
- Impaired visual acuity, as defined by difficulty reading the informed consent even
with corrective lenses.
- Recent history (within the past 6 months) of suspected substance abuse or dependence.
- History of seizures (exclusive of febrile seizures), a tic disorder, significant
tics, a current diagnosis of Tourette's Disorder.
- Taken part in a clinical trial within 30 days prior to screening.
- Diagnosis of color blindness.
- Regular use of psychoactive drugs that in the opinion of the Investigator may
confound study data/assessments
- Any other medical condition that in the opinion of the investigator may confound
study data/assessments.
We found this trial at
2
sites
7940 Floyd Curl Dr.
San Antonio, Texas 78229
San Antonio, Texas 78229
210-949-0122
Principal Investigator: Jason Miller, DO
Click here to add this to my saved trials
Little Rock, Arkansas 72211
Principal Investigator: Paul E Wylie, MD
Phone: 501-553-9987
Click here to add this to my saved trials